Iterum Therapeutics PLC expected to post a loss of 11 cents a share - Earnings Preview

Iterum Therapeutics

01/08/2025 15:43

Iterum Therapeutics PLC ITRM.OQ ITRM.O is expected to  show no change in quarterly revenue when it reports  results on August 5 for the period ending June 30 2025

​LSEG's mean analyst estimate for Iterum Therapeutics PLC is for a loss of 11 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 3.3% in the last three months. ​

Wall Street's median 12-month price target for Iterum Therapeutics PLC is $7.00, about 89.6% above its last closing price of $0.73

This summary was machine generated August 1 at 14:43 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)